异基因造血干细胞移植后巨细胞病毒感染初级预防的药物研究现状  

Research status in primaryprophylaxis therapy of cytomegalovirus infections after allogeneic hematopoietic stem cell transplantation

作　　者：谈志远 陈恳[1] 胡凯[2] 赵荣生[1] 刘维[1] TAN Zhi-yuan;CHEN Ken;HU Kai;ZHAO Rong-sheng;LIU Wei(Department of Pharmacy,Peking University Third Hospital,Beijing 100191,China;Department of Hematology,Peking University Third Hospital,Beijing 100191,China;Department of Pharmacy Administration and Clinical Pharmacy,Peking University Pharmaceutical Science,Beijing 100191,China)

机构地区：[1]北京大学第三医院药剂科,北京100191 [2]北京大学第三医院血液内科,北京100191 [3]北京大学药学院药事管理与临床药学系,北京100191

出　　处：《中国临床药理学杂志》2020年第5期580-583,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：巨细胞病毒(CMV)是一种疱疹病毒组DNA病毒,因免疫缺陷或进行异基因造血干细胞移植(Allo-HSCT)患者易发生CMV机会性感染。移植后3个月发生CMV感染的概率约为50%~60%。CMV病中最常见的为CMV间质性肺炎,死亡率可达70%。因此,对于Allo-HSCT受者,CMV的预防显得尤为重要。目前国内尚无CMV感染相关指南及共识,而由于国内外上市药物有所差异,国外指南推荐的方案需结合国内实际情况进行选用。本文将对相关指南推荐及药物研究进展进行综述,为临床提供参考。Cytomegalovirus(CMV)is a herpesvirus DNA virus,which can cause opportunistic CMV infections in patients with immunodeficiency or allogeneic hematopoietic stem cell transplantation(Allo-HSCT).Three months after transplantation,the incidence rate of CMV infection is about 50%-60%.After infection or reactivation,CMV interstitial pneumonia is the most common disease with a mortality rate up to 70%.Hence,the prevention of CMV is important to Allo-HSCT recipients.At present,there were no relevant guidelines or consensuses on CMV infection in China.Nevertheless,due to the differences between domestic and foreign drug approval,the reference value of the recommendations of foreign guidelines is limited,and therefore,this article will review the recommendations of guidelines and the research progress of related prophylactic agents,so as to provide reference for clinical practice.

关 键 词：乐特莫韦 更昔洛韦 膦甲酸钠 巨细胞病毒 异基因造血干细胞移植 

分 类 号：R978.7[医药卫生—药品]